权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

TMS-EEG investigation of prefrontal cortical excitability in depression and rTMS treatment response

TMS-EEG 研究抑郁症前额皮质兴奋性和 rTMS 治疗反应

基本信息

批准号：
9896462
负责人：
RAYMOND Y CHO
金额：
$ 20.48万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-13 至 2022-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9896462
关键词：
Action Potentials Address Antidepressive Agents Award Biological Markers Brain Chemosensitization Clinical Depressed mood Development Disease Electroencephalography Emotional Emotions Equilibrium FDA approved Functional disorder Human Impairment Investigation Ketamine Knowledge Left Link Major Depressive Disorder Measures Mental Depression Mental disorders Moods Motor Motor Cortex Neurologic Neuronal Plasticity Neurons Patients Population Prediction of Response to Therapy Prefrontal Cortex Regulation Research Safety Surrogate Markers Synapses Techniques Transcranial magnetic stimulation Treatment Efficacy Work antidepressant effect clinical biomarkers depressed patient functional disability health economics improved indexing innovation neural circuit neurobiological mechanism neuroregulation novel personalized medicine repetitive transcranial magnetic stimulation response specific biomarkers success treatment choice treatment response treatment strategy treatment-resistant depression

项目摘要

PROJECT SUMMARY Treatment of Major Depressive Disorder (MDD) is a serious clinical challenge as nearly 50% of depressed patients do not fully respond to treatment, referred to as Treatment Resistant Depression (TRD). Current antidepressants take few weeks to work and further, there are no reliable clinical biomarkers available to predict treatment response which leads to several trial-and-error attempts of different treatment strategies. The two leading challenges in MDD research are – (i) developing better treatments and (ii) developing noninvasive clinically useful biomarkers of antidepressant treatment response. The main objective of this award is to investigate prefrontal cortical excitability as neurobiological mechanisms underlying depression and antidepressant effect of rTMS in patients with TRD by using concurrent Transcranial Magnetic Stimulation- Electroencephalography (TMS-EEG). This project uses an innovative research strategy by deploying TMS-EEG to study cortical excitability in dorsolateral prefrontal cortex in TRD patients at baseline and after intermittent theta burst stimulation (iTBS), a state-of-the-art FDA approved TRD treatment. For baseline comparison with patients, demographically matched healthy controls will have TMS-EEG. The project aims will be accomplished by: 1) Investigating the prefrontal cortical excitability in patients with depression compared with healthy control subjects; 2) Investigating the effect of iTBS on prefrontal cortical excitability; and 3) Investigating the baseline dorsolateral prefrontal cortical excitability measures and its relationship to improvements in mood in patients with TRD. The findings from this study will strengthen our understanding of mechanisms underlying anti-depressant action and thus facilitate development of non-invasive surrogate markers of antidepressant response to iTBS in TRD. This work will contribute to: 1) personalized medicine in MDD by establishing markers of treatment response, 2) understanding rTMS antidepressant effect.

项目总结